INCHEON, Korea – October 30, 2025 – Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, today announced an equity investment in Arbor Biotechnologies, Inc., a leading Read More The post Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines appeared first on Arbor Biotechnologies .